What is the 13F Pro Quality Score for XNCR?

13F Pro ranks Xencor Inc (XNCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XNCR's current score at https://13fpro.ai/company/XNCR (free sign-up required for the full ranking).

Which hedge funds own the most XNCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XNCR include BlackRock,, PRIMECAP MANAGEMENT CO/CA/, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/XNCR as soon as new 13F filings post.

Where does 13F Pro source XNCR data?

All Xencor Inc fundamentals and ownership data come directly from SEC EDGAR. Xencor Inc files with the SEC under CIK 1326732. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XNCR in?

Xencor Inc (XNCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XNCR research updated on 13F Pro?

XNCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xencor Inc(XNCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326732 XNCR stock profile & AI dashboard →

13F Pro Quality Score

11.6/100

Rank #2,901 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

5.3/100

Profitability

6.0/100

Balance Sheet

10.9/100

Earnings Quality

5.8/100

Free Cash Flow

4.4/100

Institutional Flow

35.4/100

Revenue Scale

16.4/100

Dilution Risk

5.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why XNCR Scores 12/100

exact factor attribution · 2026-09-11

XNCR's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+0.3 pts

55th pct

Institutional flow

-0.7 pts

35th pct

Shareholder dilution

-2.2 pts

6th pct

Capital efficiency

-3.9 pts

11th pct

Earnings quality

-4.4 pts

6th pct

Scale

-5.0 pts

16th pct

Profitability

-6.6 pts

6th pct

Free cash flow

-6.8 pts

4th pct

Revenue growth

-8.9 pts

5th pct

Latest change (2026-08-05): 13 → 16 · ↑ Capital efficiency 10→20

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

XNCR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Xencor Inc (XNCR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XNCR at 11.6/100 on a 32-signal composite quality model, placing it at rank #2,901 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (4.4) and revenue growth (5.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xencor Inc reports quarterly revenue of $51.2M, net income of $-21.7M, free cash flow of $-56.2M. Top institutional holders of XNCR by reported 13-F value include BlackRock, PRIMECAP MANAGEMENT, BVF, based on the most recent SEC filings. XNCR trades on the Nasdaq exchange and files with the SEC under CIK 1326732. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XNCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xencor Inc directly from SEC EDGAR. Xencor Inc's 13F Pro composite quality score has ranged between 12 and 50 since 2021, currently 11.6 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Xencor Inc

Quirks, history, and lore behind XNCR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the low tens of millions, typical of a clinical-stage biotech — the real value is in the pipeline, not the income statement.
3
The History
Founded in the early 2000s, it was built around a proprietary protein engineering platform designed to make antibody drugs work better and last longer.
4
The Secret
Its core trick is Fc engineering — tweaking the non-binding end of an antibody to dial up efficacy, tune immune responses, or extend half-life in the body.
5
The Lore
It has struck licensing deals with multiple large pharma companies who want its engineering technology baked into their own antibody programs, making it a quiet behind-the-scenes force in biotech.
6
The Giveaway
The company's very name is a mashup of "Xen" and "core" — and its ticker is basically just the consonants, because apparently vowels are overrated.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$51.2M

Net Income

Q2 2026

$-21.7M

Free Cash Flow

Q2 2026

$-56.2M

ROIC

Q2 2026

-24.4%

D/E Ratio

Q2 2026

0.21

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+13.7% YoY

$125.6MFY 2025

FY22 $164.6MFY23 $174.6MFY24 $110.5MFY25 $125.6M

Net Income

+60.5% YoY

$-91.9MFY 2025

FY22 $-55.2MFY23 $-133.1MFY24 $-232.6MFY25 $-91.9M

Operating Income

+0.5% YoY

$-177.5MFY 2025

FY22 $-82.5MFY23 $-132.4MFY24 $-178.4MFY25 $-177.5M

EPS (Diluted)

+65.4% YoY

$-1.24FY 2025

FY22 $-0.93FY23 $-2.20FY24 $-3.58FY25 $-1.24

Total Assets

-8.0% YoY

$875.5MFY 2025

FY22 $846.3MFY23 $965.1MFY24 $951.9MFY25 $875.5M

Total Debt

-26.8% YoY

$119.7MFY 2025

FY22 $0.00FY23 $42.4MFY24 $163.6MFY25 $119.7M

Op. Cash Flow

+33.2% YoY

$-135.1MFY 2025

FY22 $24.5MFY23 $-77.9MFY24 $-202.2MFY25 $-135.1M

Free Cash Flow

+33.6% YoY

$-138.3MFY 2025

FY22 $-14.0MFY23 $-96.4MFY24 $-208.3MFY25 $-138.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$125.6M +13.7%	$110.5M -36.7%	$174.6M +6.1%	$164.6M -40.2%	$275.1M +124.2%	$122.7M
Net Income	$-91.9M +60.5%	$-232.6M -74.7%	$-133.1M -141.3%	$-55.2M -166.8%	$82.6M +219.2%	$-69.3M
Operating Income	$-177.5M +0.5%	$-178.4M -34.8%	$-132.4M -60.5%	$-82.5M -288.4%	$43.8M +157.0%	$-76.8M
EPS (Diluted)	$-1.24 +65.4%	$-3.58 -62.7%	$-2.20 -136.6%	$-0.93 -167.9%	$1.37 +213.2%	$-1.21
Total Assets	$875.5M -8.0%	$951.9M -1.4%	$965.1M +14.0%	$846.3M +1.0%	$838.2M +19.2%	$703.2M
Total Debt	$119.7M -26.8%	$163.6M +286.3%	$42.4M	$0.00	—	—
Operating Cash Flow	$-135.1M +33.2%	$-202.2M -159.5%	$-77.9M -418.3%	$24.5M +245.3%	$-16.9M -236.8%	$-5.0M
Free Cash Flow	$-138.3M +33.6%	$-208.3M -116.1%	$-96.4M -587.9%	$-14.0M +53.5%	$-30.2M -94.0%	$-15.5M

Get alerted when XNCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xencor Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XNCR

BlackRock, Inc.
$219.8M13,651,261 sh
PRIMECAP MANAGEMENT CO/CA/
$163.9M10,181,322 sh
BVF INC/IL
$114.9M7,133,720 sh
RTW INVESTMENTS, LP
$109.1M6,777,461 sh
RA CAPITAL MANAGEMENT, L.P.
$84.9M5,274,274 sh
STATE STREET CORP
$79.8M4,954,016 sh
VANGUARD CAPITAL MANAGEMENT LLC
$52.8M3,278,802 sh
TCG Crossover Management, LLC
$39.5M2,452,138 sh
PRICE T ROWE ASSOCIATES INC /MD/
$37.9M2,356,409 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$35.7M2,215,690 sh

Fund	Value	Shares
BlackRock, Inc.	$219.8M	13,651,261
PRIMECAP MANAGEMENT CO/CA/	$163.9M	10,181,322
BVF INC/IL	$114.9M	7,133,720
RTW INVESTMENTS, LP	$109.1M	6,777,461
RA CAPITAL MANAGEMENT, L.P.	$84.9M	5,274,274
STATE STREET CORP	$79.8M	4,954,016
VANGUARD CAPITAL MANAGEMENT LLC	$52.8M	3,278,802
TCG Crossover Management, LLC	$39.5M	2,452,138
PRICE T ROWE ASSOCIATES INC /MD/	$37.9M	2,356,409
VANGUARD PORTFOLIO MANAGEMENT LLC	$35.7M	2,215,690

Companies Similar to XNCR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AVTX

Avalo Therapeutics, Inc.

AI score

Very similar · 11 shared holders

TCG Crossover Management, LLC BVF INC/IL RA CAPITAL MANAGEMENT, L.P.

STOK

Stoke Therapeutics, Inc.

AI score

Very similar · 11 shared holders

RTW INVESTMENTS, LP BVF INC/IL BAKER BROS. ADVISORS LP

WVE

Wave Life Sciences, Inc.

AI score

Very similar · 11 shared holders

RA CAPITAL MANAGEMENT, L.P.PRIMECAP MANAGEMENT CO/CA/RTW INVESTMENTS, LP

DTIL

PRECISION BIOSCIENCES INC

AI score

Very similar · 4 shared holders

Velan Capital Investment Management LP Lynx1 Capital Management LP Susquehanna Portfolio Strategies, LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP Deep Track Capital, LP ADAR1 Capital Management, LLC

ENTA

ENANTA PHARMACEUTICALS INC

AI score

Very similar · 5 shared holders

Deep Track Capital, LP ADAR1 Capital Management, LLC Susquehanna Portfolio Strategies, LLC

TRDA

Entrada Therapeutics, Inc.

AI score

Very similar · 7 shared holders

BAKER BROS. ADVISORS LP TCG Crossover Management, LLC Susquehanna Portfolio Strategies, LLC

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP RTW INVESTMENTS, LP Susquehanna Portfolio Strategies, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XNCR on your watchlist

Track score changes the day Xencor Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XNCR a good stock to buy?

13F Pro's AI-powered analysis of Xencor Inc (XNCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XNCR are available on the XNCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XNCR is classified as a small company.

Which hedge funds own XNCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XNCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xencor Inc's investment landscape.